BIOTEST AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.6 EUR | 0.00% |
|
0.00% | -2.35% |
| 07/05 | Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 19/04 | Biotest Launches New Plasma Collection Center in Germany | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 64Cr 69Cr 5.76TCr | Sales 2025 * | 71Cr 77Cr 6.45TCr | Capitalization | 136.92Cr 148.79Cr 12TCr |
|---|---|---|---|---|---|
| Net income 2024 * | -40L -43.47L -36Cr | Net income 2025 * | 5.9Cr 6.41Cr 534.09Cr | EV / Sales 2024 * | 3.19 x |
| Net Debt 2024 * | 66Cr 72Cr 5.98TCr | Net Debt 2025 * | 66Cr 72Cr 6TCr | EV / Sales 2025 * | 2.85 x |
| P/E ratio 2024 * |
-271
x | P/E ratio 2025 * |
18.4
x | Employees | 2,426 |
| Yield 2024 * |
0.07% | Yield 2025 * |
2.25% | Free-Float | 29.83% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 month | -0.48% | ||
| 3 months | -0.95% | ||
| 6 months | -2.35% | ||
| Current year | -2.35% |
1 week
41.00
41.60
1 month
41.0041.80
Current year
40.4043.00
1 year
39.6044.00
3 years
28.3044.60
5 years
17.2044.60
10 years
11.7044.60
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 41.6 | 0.00% | 100 |
| 16/24/16 | 41.6 | 0.00% | 100 |
| 15/24/15 | 41.6 | 0.00% | 100 |
| 14/24/14 | 41.6 | 0.00% | 100 |
| 13/24/13 | 41.6 | 0.00% | 739 |
Delayed Quote Xetra, May 17, 2024 at 09:06 pm IST
More quotes
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
27.6
EUR
Average target price
37
EUR
Spread / Average Target
+34.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.32% | 9.04TCr | |
| +3.68% | 4.14TCr | |
| -10.90% | 3.36TCr | |
| +58.05% | 2.57TCr | |
| -19.56% | 1.47TCr | |
| -9.06% | 1.28TCr | |
| -11.34% | 1.17TCr | |
| -43.53% | 1.14TCr | |
| +3.75% | 879.22Cr |
- Stock Market
- Equities
- BIO3 Stock
- BIO Stock
